Research from Columbia University Irving Medical Center Broadens Understanding of Prostate Cancer [Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)]

Media coverage

• Title	Research from Columbia University Irving Medical Center Broadens Understanding of Prostate Cancer [Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)]
  Media name/outlet	Immunotherapy Daily
  Country/Territory	United States
  Date	30/03/23
  Persons	Shalini Singh Yadav